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Radiation Followed by Gemcitabine Alone or by Combined
Gemcitabine and Docetaxel in Stage III A/B Unresectable
Non-small Cell Lung Cancer
Benjamin Movsas, MD,* Corey J. Langer, MD,† Helen J. Ross, MD,‡ Luhua Wang, MD,§
Robert M. Jotte, MD, PhD, Steve Feigenberg, MD,¶ Feng Xu, MD,# Chao H. Huang, MD,**
Matthew J. Monberg, MS,†† and Coleman K. Obasaju, MD, PhD††
Purpose: Southwest Oncology Group 9504 demonstrated the feasi-
bility and potential benefit of docetaxel consolidation after etopo-
side, cisplatin, and radiotherapy in patients with locally advanced
non-small cell lung cancer. Our study assessed consolidation with
either gemcitabine alone or with docetaxel after identical chemora-
diation as used in Southwest Oncology Group 9504.
Methods: Patients with stage III non-small cell lung cancer and
good performance status were included. Treatment consisted of
concurrent cisplatin 50 mg/m2 on days 1 and 8 plus etoposide 50
mg/m2 on days 1 to 5 for two 28-day cycles plus radiotherapy (62
Gy, 2 Gy daily in 31 fractions over 7 weeks), followed by random-
ization to either gemcitabine 1000 mg/m2 on days 1 and 8 (G) or
gemcitabine 1000 mg/m2 on days 1 and 8 plus docetaxel 75 mg/m2
on day 1 (GD) every 21 days for three cycles.
Results: Eighty-three patients were entered, 81 received induction
therapy, and 64 were randomized (32 in each arm). Grade 3 or four
events, including neutropenia (56.3% vs. 28.1%, p  0.03), anemia
(18.8% vs. 3.1%, p  0.05), and fatigue (15.6% vs. 6.3%, p  NS),
were more frequent with GD compared with G. Among all patients,
median survival from registration was 20.8 months (95% confidence
interval: 16.4–33.8), and 2-year survival was 46.7% (95% confi-
dence interval: 35.6–57.1). From randomization, median progres-
sion-free survival was 5.4 months for G and 13.4 months for GD,
and median survival was 16.1 months for G and 29.5 months for
GD. Two-year survival rates were 40.6% for G and 55.7% for GD.
Conclusion: The doublet, as expected, resulted in more toxicity,
particularly myelosuppression and fatigue. Survival associated with
the GD treatment arm of this trial exceeds that of previously
reported trials.
Key Words: Consolidation, Stage IIIA/B, NSCLC, Docetaxel,
Gemcitabine.
(J Thorac Oncol. 2010;5: 673–679)
Approximately 30% of patients diagnosed with non-smallcell lung cancer (NSCLC) have locally advanced dis-
ease.1 Stage III disease represents a heterogeneous group of
patients with variable prognoses based on a variety of demo-
graphic, clinical, and biologic features.2,3 Some stage IIIA
tumors (T3 and N1) are still treated primarily by surgical
resection. Tumors with ipsilateral mediastinal nodal involve-
ment (T1–3 and N2) are managed either by combined radio-
therapy (RT) and chemotherapy or by induction chemo-
therapy or chemoradiotherapy, followed by surgical
resection. Most stage IIIB (T4 or N3) tumors are treated
with RT and chemotherapy.4 Chemotherapy administered
concurrently with RT improves locoregional control by
radioenhancement and overall survival (OS) compared
with radiation alone or sequential chemoradiotherapy
likely due to a reduction in distant micrometastases at
systemically active chemotherapy doses.5–7
Several randomized trials have established the superi-
ority of concurrent chemoradiotherapy over sequential che-
motherapy followed by RT.8–11 The use of full-dose consol-
idation docetaxel (D) after chemoradiotherapy gained
popularity after the completion of Southwest Oncology
Group (SWOG) 9504.12 This trial used etoposide, cisplatin,
and RT followed by three cycles of docetaxel. This phase II
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nonrandomized trial produced the best survival reported in
stage III NSCLC: median survival of 27 months, a 29%
5-year survival, and a median progression-free survival (PFS)
of 16 months.12 These results were especially favorable
compared with SWOG 9019, in which the concurrent
chemoradiation regimen was identical, but etoposide and
cisplatin were used in lieu of docetaxel during the consol-
idation period.13
It was a natural step to investigate a modern doublet
consolidation regimen in an attempt to improve on SWOG
9504. Preclinical data suggest that gemcitabine (G) and
taxanes may act synergistically,14 as the agents have inde-
pendent mechanisms of action, independent activity in lung
cancer, and nonoverlapping toxicities. This randomized phase
II study was developed to assess the feasibility and efficacy of
consolidation with either single-agent G or combination GD
after the same chemoradiation used in SWOG 9504.
PATIENTS AND METHODS
Eligibility Criteria
Patient eligibility was similar to SWOG 9504.12 Key
differences from SWOG 9504 were the inclusion of unresect-
able stage IIIA and IIIB patients and exclusion of Eastern
Cooperative Oncology Group performance status in two pa-
tients. Patients had histologic or cytologic proof of a single,
primary bronchogenic NSCLC. Pathologic diagnosis from
involved mediastinal or supraclavicular lymph nodes alone
was accepted if a distinct primary lesion was evident on
radiographs. Patients with 2 distinct parenchymal primary
lesions were ineligible. Inoperable stage IIIA disease was
determined by the presence of multiple or bulky N2 medias-
tinal lymph nodes. Stage IIIB disease was determined either
by N3 involvement from pathologically documented con-
tralateral mediastinal or by supraclavicular nodes not extend-
ing into the cervical region or by T4 invasion of mediastinal
structures, including the heart, great vessels, trachea, carina,
esophagus, or vertebral body. Patients who had a separate
satellite nodule in the same lobe as the primary lesion
(T4/Stage IIIB disease) were eligible if the nodule could be
encapsulated within a tolerable radiation portal. Initial stag-
ing included brain imaging (either computed tomography
CT or magnetic resonance imaging) and a bone scan.
Patients with pleural effusions were eligible only if there was
negative cytology or the effusion was inaccessible to thora-
centesis. Patients with pericardial effusions or weight loss
10% within the previous 6 months were ineligible.
Patients were required to have measurable disease by
chest x-ray or CT scan. Prior chemotherapy or RT for lung
cancer was not permitted. Prior exploratory diagnostic sur-
gery was permitted. Pulmonary function requirements in-
cluded a forced expiratory volume in 1 second (FEV1) 1
liter by spirometry. Organ function requirements included an
absolute neutrophil count (ANC)1500, platelets100,000,
serum bilirubin 1.5 mg/deciliter, and serum glutamic ox-
aloacetic transaminase (SGOT) 1.5 institutional upper
limits of normal (IULN), unless the abnormality was caused
by documented benign disease. Patients with benign disease
required a serum glutamic oxaloacetic transaminase 2.5
IULN and alkaline phosphatase 2.5 IULN. Patients were
also required to have adequate organ and bone marrow function
including an estimated creatinine clearance 50 milliliter/min
(using the modified Cockcroft and Gault formula).15 Patients
were required to be 18 years of age; patients who were breast
feeding, pregnant, or who had serious concomitant disorders
were ineligible. The institutional review board of each site
approved the protocol before study initiation. This study
was performed in compliance with the principles of good
clinical practice, the Helsinki Declaration, and federal and
institutional guidelines. All participating patients provided
written informed consent before undergoing any study
procedure or receiving any study therapy.
Study Design
Treatment consisted of concurrent chemoradiation fol-
lowed by randomization to a consolidation phase of three
cycles of G or GD. The concurrent chemoradiation compo-
nent consisted of cisplatin 50 mg/m2 on days 1 and 8 and
etoposide 50 mg/m2 on days 1 to 5 every 4 weeks for two
cycles as on SWOG 9504. RT (62 Gy) was delivered over 7
weeks (2 Gy daily in 31 fractions) starting within 24 hours of
the first day of chemotherapy. Heterogeneity dose corrections
were not used. Weekly complete blood cell counts and
chemistries were required during chemoradiotherapy. Spe-
cific dose modification criteria were provided for myelotox-
icity and renal toxicity, using the National Cancer Institute
Common Toxicity Criteria Version 2.0 guidelines.16
The target volume for RT was defined by CT scan,
pathologic information, positron emission tomography scan
(if available), and clinical evaluation. The treatment volume
included the gross tumor and lymph nodes that were patho-
logically involved, metabolically active, or 1 cm on CT
plus up to a 1.5 cm margin (to the block). RT dose was
prescribed to a 3-dimensional conformal isodose line that
adequately covered the treatment volume. Field orientation
was selected to minimize the volume of irradiated lung
outside the target volume, especially the contralateral lung.
Normal tissue tolerance criteria were provided as fol-
lows: the total lung volume exceeding V20 was30%, mean
esophageal dose was 34 Gy, maximum spinal cord dose
was 48 Gy, and the whole heart was not to exceed 40 Gy (up to
50% of the cardiac silhouette could receive up to 60 Gy). RT did
not include elective nodal coverage. RT interruptions were
strongly discouraged but were allowed in the circumstances of
grade 3 or 4 esophagitis or grade 4 neutropenia with fever.
Patients were restaged at week 10 using CT at a
minimum. Patients with evidence of disease recurrence or
progression (by RECIST)17 were removed from the study.
Patients without evidence of disease progression or distant
metastases were then randomized to the consolidation phase
of the trial. Consolidation consisted of single-agent G 1000
mg/m2 on days 1 and 8 every 3 weeks for three cycles (G) or
combination of G 1000 mg/m2 on days 1 and 8 plus D 75
mg/m2 on day 1 every 3 weeks for three cycles (GD). Before
the start of each cycle, G or GD were administered only if
ANC was 1.5  109/liter and platelets 100  109/liter.
On day 8, if ANC was 1.0  109/liter or platelets were
75  109/liter, patients received 75% of the planned G
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dose. For ANC0.5 109/liter, G was withheld to allow for
recovery to minimum acceptable counts. Consolidation dos-
ing was reduced by 50% after any grade 3 nonhematologic
event (except nausea, vomiting, or alopecia) and withheld to
allow for recovery after a grade 4 event.
Study Evaluation and Statistical Methods
The primary endpoint of this study was 2-year sur-
vival. Assuming 10% of patients would be lost to follow-
up, the sample size goal of each treatment arm was 51
patients. This would provide 81% power to test whether the
true 2-year survival rate was30% (H0), versus a true 2-year
survival rate of 50% (HA). Given the 2-year survival rate of
54% observed in SWOG 9504, either regimen would be
considered promising if it achieved a 2-year survival of 50%
or greater.
OS and PFS were measured from the date of registra-
tion to the date of death from any cause or the first date of
documented progression. OS and PFS were censored at the
date of the last follow-up visit for patients who were still alive
or who had not progressed and were analyzed using Kaplan-
Meier test.18 Two-sided 95% confidence intervals (CIs) for
tumor response were calculated using exact binomial proba-
bilities. Best tumor response was defined by RECIST crite-
ria.17 Positron emission tomography was not required for
response assessments. Tumor assessments occurred at base-
line, at week 10 restaging, within 2 weeks of the last dose of
consolidation chemotherapy, and continued at 3-month inter-
vals for the first 2 years. Toxicity was summarized for the
consolidation phase of treatment with the modified Medical
Dictionary for Regulatory Activities.
RESULTS
Patient Characteristics
Patient disposition is summarized in Figure 1. Between
March 14, 2003, and December 31, 2006, 83 patients were
entered at 13 sites in the United States, two in China, two in
Argentina, and two in Korea. Of these, 82 received induction
chemoradiation and 64 were randomized in the consolidation
phase of the trial (32 to each treatment group). Baseline
demographics of the intent-to-treat (ITT) and randomized
populations from the study are summarized in Table 1. The
characteristics of patients randomized to G and GD were
similar.
Study of Drug Administration and Toxicity
Of the 82 patients who received induction therapy, 18
discontinued treatment before randomization to consolidation
FIGURE 1. Patient disposition.





Median age, yr (range) 59.0 (25–79) 59.5 (44–71) 59.5 (25–72)
Gender, n (%)
Male 66 (79.5%) 27 (84.4%) 26 (81.3)
Female 17 (20.5%) 5 (15.6%) 6 (18.8)
Ethnicity, n (%)
Caucasian 44 (53.0) 18 (56.3) 19 (59.4)
Asian 32 (38.6) 13 (40.6) 10 (31.3)
Other 7 (8.4) 1 (3.1) 3 (9.3)
ECOG PS, n (%)
0 32 (38.6) 11 (34.4) 13 (40.6)
1 51 (61.4) 21 (65.6) 19 (59.4)
Histology, n (%)
Squamous 43 (51.8) 16 (50.0) 17 (53.1)
Adenocarcinoma 27 (32.5) 12 (37.5) 9 (28.1)
Large cell 7 (8.4) 2 (6.3) 3 (9.4)
Mixed 1 (1.2) 0 (0.0) 1 (3.1)
Other 5 (6.0) 2 (6.3) 2 (6.3)
Initial stage, n (%)
IIIA 23 (27.7) 5 (15.6) 11 (34.4)
IIIB 56 (67.5) 26 (81.3) 19 (59.4)
Unavailable 4 (4.8) 1 (3.1) 2 (6.3)
Primary tumor location,
n (%)
Left upper lobe 20 (24.1) 8 (25.0) 7 (21.9)
Left lower lobe 12 (14.5) 4 (12.5) 5 (15.6)
Left lingula 2 (2.4) 1 (3.1) 1 (3.1)
Right upper lobe 35 (42.2) 17 (53.1) 12 (37.5)
Right middle lobe 6 (7.2) 0 (0.0) 4 (12.5)
Right lower lobe 7 (8.4) 2 (6.3) 3 (9.4)
Unknown 1 (1.2) 0 (0.0) 0 (0.0)
ECOG, eastern cooperative oncology group; N, number of patients; n, number in
group; PS, performance status.
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therapy. Of those, eight discontinued because of PD, four
because of patient decision, three because of an adverse event,
and three because of death. Causes of death were pulmonary
embolism, abdominal aortic aneurysm with complicated dissec-
tion, and pneumonia. Sixty-four patients (78.0%) proceeded to
consolidation therapy, with 32 patients receiving G and 32
receiving GD. Twenty-nine patients (90.6%) received all three
planned cycles of G, with two patients receiving one cycle
and one patient receiving two cycles. Twenty-two patients
(68.8%) received all three planned cycles of GD; two patients
received one cycle and eight received two cycles.
Toxicity rates among the 64 patients receiving consol-
idation therapy are summarized in Table 2. One patient
receiving GD died after withdrawal of mechanical ventilation
related to radiation pneumonitis and respiratory failure.
Grade 3 or 4 hematologic events, including neutropenia (56.3
vs. 28.1%, p  0.03), anemia (18.8% vs. 3.1%, p  0.05),
and febrile neutropenia (6.3% vs. 0.0%) were more frequent
in the GD arm compared with the G arm. Grade 3 or 4
nonhematologic events generally occurred with a frequency
of 10%; however, the rate of grade 3 fatigue was greater in
the GD arm compared with G (15.6% vs. 6.3%, p  not
significant).
Response
Best tumor response to induction therapy is summa-
rized in Table 3. Among all patients, there was 1 CR and 48
PRs, for a response rate of 59.0%. The response rate to
induction therapy was slightly greater among patients ran-
domized to the GD treatment group compared with G (68.8%
vs. 59.4%). After randomization to consolidation therapy, one
patient in the G treatment group and three patients in the GD
treatment group achieved previously undocumented CRs, and
four patients in the G treatment group and one patient in the
GD treatment group achieved previously undocumented PRs.
Counting both induction and consolidation phases of the trial,
the response rates were 75.0% in the G treatment group (95%
CI: 56.6–88.5) and 81.3% in the GD treatment group (95%
CI: 63.6–92.8).
Progression-Free Survival and OS Analysis
Figure 2A summarizes OS for all patients registered in
the study. Among the ITT population (including patients who
did not proceed to consolidation), median survival from
registration was 20.8 months (95% CI: 16.4–33.8, censor-
ship  35%). One-year survival for the ITT population was
66.7% (95% CI: 57.3–74.5), 2-year survival was 46.7% (95%
CI: 35.6–57.1), and 3-year survival was 37.3% (95% CI:
26.3–48.2).
Median follow-up time from randomization was 41.5
months (range: 23.7–67.5) for patients in the G treatment
group and 41.3 months (range: 15.5–55.7) in the GD treat-
ment group. At the time of this analysis, 27 patients in the G
treatment group (84.4%) and 26 patients in the GD treatment
group (81.3%) had experienced disease progression. Figure
2B summarizes PFS for both treatment arms. Median PFS
from randomization was 5.4 months in the G treatment group
(95% CI: 2.7–7.9) and 13.4 months in the GD treatment
group (95% CI: 4.6–23.3).
At the time of this analysis, 20 patients in the G
treatment group (62.5%) and 18 patients in the GD treatment
group (56.3%) had died. Figure 2C summarizes OS for both
treatment groups. Median OS from randomization was 16.1
months in the G treatment group (95% CI: 9.8–34.0) and 29.5
months in the GD treatment group (95% CI: 16.4–52.0).
Estimated survival rates from randomization were 65.6% at 1
year (95% CI: 46.9–79.3), 40.6% at 2 years (95% CI:
23.8–56.8), and 30.5% at 3 years (95% CI: 14.2–48.5) for G;
and 71.9% at 1 year (95% CI: 52.9–84.3), 55.7% at 2 years
(95% CI: 36.8–70.9), and 39.8% at 3 years (95% CI: 22.1–
56.9) for GD.
DISCUSSION
The development of newer chemotherapeutic agents
with activity in NSCLC provides the opportunity to explore
novel approaches in the treatment of stage IIIB disease. This
study indicates that both G and GD after chemoradiation in
locally advanced NSCLC are well tolerated. Consolidation
with the doublet, as expected, resulted in more toxicity,
TABLE 2. Summary of Toxicity
Gemcitabine (N  32) Gemcitabine and Docetaxel (N  32)
Toxicity, n (%) Grade 2 Grade 3 Grade 4 Grade 2 Grade 3 Grade 4
Anemia 1 (3.1) 1 (3.1) 0 (0.0) 12 (37.5) 4 (12.5) 2 (6.3)
Febrile neutropenia 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (6.3)
Neutropenia 5 (15.6) 7 (21.9) 2 (6.3) 0 (0.0) 8 (25.0) 10 (31.3)
Thrombocytopenia 4 (12.5) 2 (6.3) 0 (0.0) 2 (6.3) 6 (18.8) 0 (0.0)
Fatigue 1 (3.1) 2 (6.3) 0 (0.0) 4 (12.5) 5 (15.6) 0 (0.0)
Pneumonia 1 (3.1) 1 (3.1) 0 (0.0) 1 (3.1) 2 (6.3) 0 (0.0)
Radiation pneumonitisa 0 (0.0) 1 (3.1) 0 (0.0) 3 (9.4) 0 (0.0) 0 (0.0)
Dyspnea 0 (0.0) 1 (3.1) 0 (0.0) 3 (9.4) 2 (6.3) 1 (3.1)
Hypotension 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (6.3) 0 (0.0)
Alopecia 1 (3.1) — — 1 (3.1) — —
a One patient in the gemcitabine and docetaxel group (3.1%) experienced grade 5 radiation pneumonitis.
N, number of patients; n, number in group.
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particularly myelosuppression and fatigue. Consistent with
the relative tolerability of each treatment arm, a greater
percentage of patients in the single-agent arm received all
three planned cycles of consolidation therapy.
The relative tolerability of the treatment arms, however,
must be balanced against efficacy. Despite higher toxicity in
the GD arm and the greater delivery of the planned three
cycles of consolidation in the G arm, survival analysis sug-
gests that doublet chemotherapy is preferred. The possibility
that some of the survival difference between arms may have
been related to imbalances of stage cannot be ruled out. At
the same time, in the chemoradiation setting, stage (IIIA vs.
TABLE 3. Summary of Response Rates











Complete response 1 (1.2) 1 (3.1) 0 (0.0) 2 (6.3) 3 (9.4)
Partial response 48 (57.8) 18 (56.3) 22 (68.8) 22 (68.8) 23 (71.9)
Stable disease 19 (22.9) 13 (40.6) 5 (15.6) 8 (25.0) 1 (3.1)
Progressive disease 8 (9.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Unknown 7 (8.4) 0 (0.0) 5 (15.6) 0 (0.0) 4 (12.5)
Values are expressed as n (%).
FIGURE 2. A, Overall survival for the intent-to-treat population (N  83), measured from registration. B, Progression-free
survival for the consolidation population (N  64), measured from randomization. C, Overall survival for the consolidation
population (N  64), measured from randomization.
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IIIB) is typically not a significant predictor of survival. For
example, in the Hoosier Oncology Group (HOG) phase III
study analysis, IIIA versus IIIB status was not predictive of
outcome on either univariate or multivariate analysis.2
Table 4 summarizes key studies in stage III NSCLC
including this study. Unlike the S9504 trial, which exclu-
sively enrolled stage IIIB patients, 27.7% of patients in this
trial were stage IIIA. Median age (59.0) and gender distribu-
tion (79.5% male) were similar to studies S9504 and S9019.
In this trial and across others, including S9504, approxi-
mately 75% of patients receiving chemoradiation were able to
proceed to consolidation therapy. Given the heterogeneity of
locally advanced disease and the preliminary nature of the
results of this study, efficacy comparisons should be made
with caution. Despite these limitations, the median survival of
21 months for all patients in this trial (including those who
did not proceed to consolidation) was similar to that for all
patients in SWOG 0023 (19 months)19,20 and HOG 01-24 (21
months),21 but less than that reported in SWOG 9504 (26
months).12,22 SWOG 0023 randomized patients to gefitinib or
placebo after induction chemoradiation and consolidation
with D. In SWOG 0023, the maintenance arm did poorly
relative to the control arm (OS  23 months vs. 35 months),
which reflected the adverse effect of gefitinib on survival. It
is important to note that this trial and SWOG 9504 trial were
both phase II trials, whereas SWOG 0023 and HOG 01-24
were phase III trials.
When examining individual treatment arms, survival
associated with the GD treatment arm of this trial exceeds
that of previously reported trials. The 59% survival rate at
2-year and 33-month median survival associated with GD
compares with the 54% survival rate at 2-year and 26-month
median survival time of the previous most promising trial,
SWOG 9504.12,22 Two-year survival exceeded the target of
50% from the study design (indicating that a treatment was
promising) with GD but not with G. Furthermore, the study
was adequately powered to reject the null hypothesis that the
true 2-year survival rate associated with GD was 30%.
SWOG 0023 reported response rates associated with
induction chemoradiation and consolidation phases of the
trial.19,20 Induction chemoradiation was associated with a
response rate of 53% and after docetaxel consolidation,
response rate increased to 76%. This compares with a re-
sponse rate of 59.0% to induction therapy in this trial, and
response rates after consolidation treatment increased
to75.0% for G and to 81.3% for GD. These rates indicate that
chemotherapy is highly active in this patient population,
particularly in the subset eligible for consolidation.
HOG 01-24 challenged the use of consolidation therapy
with D.21 In that randomized trial, there was no survival
benefit associated with consolidation docetaxel compared
with standard observation following the same chemoradio-
therapy used in SWOG 9504.21 Three important points need
to be made with respect to HOG 01-24: (1) the study was
closed early with only 147 patients ultimately randomized;
(2) the standard arm out-performed historic controls; and (3)
there was an imbalance in baseline FEV1 and pulmonary
function favoring the control arm.21 In particular, further
analysis of this study demonstrated that FEV1 was indeed a
significant predictor of survival on multivariate analysis (p 
0.01).2 The lack of improvement observed with the experi-
mental arm in HOG 01-24 was possibly related to the imbal-
anced pulmonary function tests among treatment arms at
baseline, which favored the control arm.
As noted by Govindan et al.,3 it seems peculiar that the
guidelines suggest four cycles of chemotherapy for stage IV
patients but two cycles for stage III patients. To obtain an
optimal systemic effect, one would advocate in favor of four
or more cycles, as long as there were no untoward delays
in initiating RT. Moreover, the combination of two sys-
temic agents together is considered a standard approach
concurrent with thoracic RT in stage III disease and as
primary therapy in stage IV disease. It makes sense then
that two systemic agents together are likely to be more
efficacious than single agents in the setting of consolida-
tion therapy after chemoradiation.
This study was terminated before reaching the full
sample size of 51 patients per arm of consolidation because of
slow accrual. During the duration of the study, an average of
1.4 patients per month received consolidation therapy. At that
rate, the study would have required an additional 26 months
of accrual to reach the full sample size. This study was not
designed to formally test differences between the two treat-
ment arms. However, it is possible that the results associated
with the G arm were related to unfavorable patient charac-
teristics at baseline and relatively low accrual numbers.








Grade 3 or 4
FN During
Consolidation 2-yr Survival %b 3-yr Survival %b
MS by Arm
(mo)b
SWOG 9504 83 78 26 Docetaxel 9% 54 37 —
SWOG 0023 571 75.1 19 Docetaxel 5% 42 NR —
HOG 01-24 203 72.4 21 Docetaxel 11% Between 45–50 27 21.5
Observation 0% 50 28 24.1
Current trial 83 77.1 21 Gemcitabine 0% 44 36 33
Gemcitabine/docetaxel 6% 59 44 19
a This reflects the % of patients receiving chemoradiation who proceeded to the consolidation phase of the trial. All patients in HOG 01-24 who were randomized, including those
receiving standard observation, were included in this figure.
b Survival in this table is measured from patient registration.
FN, febrile neutropenia; HOG, hoosier oncology group; MS, median survival; NR, not reported; SWOG, southwest oncology group.
Movsas et al. Journal of Thoracic Oncology • Volume 5, Number 5, May 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer678
An ongoing multicenter, randomized phase III trial
(NCT00686959) may help to better define the role of consol-
idation in the locally advanced setting.23 This trial is expected
to randomize approximately 600 patients with nonsquamous
histology to receive consolidation with pemetrexed after
chemoradiation with pemetrexed plus cisplatin (arm A) or
consolidation with any other cytotoxic chemotherapy of in-
dividual physician choice after chemoradiation with etopo-
side plus cisplatin (arm B).23 Including a unique agent such as
pemetrexed that has already demonstrated a potential advan-
tage in PFS in the maintenance setting in stage IV disease24
is an attractive prospect. However, the impact of this ongoing
trial will be limited to defining the role of pemetrexed in
patients with nonsquamous histology for locally advanced
nonmetastatic disease and its feasibility with concurrent RT.
The issue of consolidation chemotherapy in this setting re-
mains still open. Data from this study incorporating D and G
indicate that consolidation therapy, as an investigational con-
cept, should be pursued.
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